Skip to main content
Premium Trial:

Request an Annual Quote

Paulette Gray New Director of NCI Extramural Activities; Thure Etzold to Resign as Lion CEO; Scott Kahn Leaves Accelrys for Illumina; Rebecca Caffrey Goes to Asterand from Ciphergen; Michael Catelani Joins Benitec as CFO from Axon, and Others

Paulette Gray has become director of the division of extramural activities of the National Cancer Institute, NCI said yesterday. She had been the division's deputy director, then acting and deputy director, since 1997. The division of extramural activities coordinates all of NCI's extramural programs and grants. Gray joined NCI in 1984 as a special review officer, moving to different positions from there. She holds a PhD in cellular and developmental biology and an MS in mycology from AtlantaUniversity, and a BS in biology from TuskegeeUniversity in Alabama.


 

Thure Etzold will resign as CEO of Lion Bioscience "in the near future" as the company seeks to sell its bioinformatics business, Lion said today. Etzold is the inventor of SRS, Lion's flagship bioinformatics product. Several Lion managers are interested in buying out the bioinformatics business, as an alternative to a sale to another company.


 

Scott Kahn has been appointed as vice president and chief information officer of Illumina, the company said last week. He joins Illumina from Accelrys, where he was chief scientific officer. Kahn holds a PhD in theoretical organic chemistry from the Universityof California, Irvine. An Accelrys spokesman told BioInform, GenomeWeb News' sister publication, that Kahn left the company a month ago, and that Accelrys is currently seeking a replacement.


 

Rebecca Caffrey has become business development manager of tissue provider Asterand, the Detroit, Mich.-based company said this week. She joins the company from Ciphergen Biosystems, where she was a business development and product manager.


 

Michael Catelani has become chief financial officer of Benitec, the company said last week. Catelani, who has been a Benitec consultant since January, joins the company from an Australian biotech company. Prior to that, he held various positions, including vice president and chief financial officer, at Axon Instruments. Catelani holds an MBA from the Universityof California, Davis.


 

Stefan Muellner has become chief financial officer of Protagen, replacing Helmut Meyer, who will focus on his academic appointment, the German proteomics company said last week. Previously, he held R&D management positions at Henkel and Hoechst. Meyer, a professor at the Ruhr-University Bochum and chair of the human brain proteome initiative of the Human Proteome Organization, will join the company's board of directors, replacing Achim Riemann, who will leave the board.


 

Robert Negm has become vice president of business development for GenTel BioSurfaces, the Madison, Wis.-based biochip firm said this week. He comes to GenTel from Whatman Schleicher & Schuell BioScience, where he was director of business bevelopment.  Prior to that, he was a program director with the National Cancer Institute.


 

Michael Kallelis has become vice president of manufacturing of Archemix, the Cambridge, Mass.-based aptamer company said on Tuesday. He comes to Archemix from Avecia Biotechnology, where he was executive vice president and general manager and managed an oligonucleotide synthesis plant. In the past, he also held positions at BostonBioSystems, BioSepra, and Millipore.


 

Martin Schmieg has become senior vice president and chief financial officer of Isolagen, the Exton, Pa.-based company said on Tuesday. Most recently, he was senior vice president and CFO of Sirna Therapeutics. Schmieg holds a degree from La SalleUniversity.


 

Gregory Kellog has become chief technology officer of Protiveris, the Rockville, Md.-based company said on Tuesday. He is the former vice president of research at Network Biosystems where he helped develop a microfabrication-based electrophoresis system for forensic applications. Kellogg holds a PhD in physics from HarvardUniversity.


 

David Champagne has been promoted to vice president and general manager of the informatics business of Thermo Electron, the company said on Monday. He succeeds Jo Webber, who recently left the company to spend time sailing the Mediterranean, according to the company. Champagnejoined Thermo in 2003 and was most recently its divisional commercial director. In the past, he held positions at Lotus Development and early-stage software companies. Champagneholds an MBA from BryantUniversity and a BS in industrial engineering from the Universityof Massachusetts.


 

Thomas Caskey has joined the board of directors of MDS, the company said today. He is a managing director of Cogene BioTech Ventures. In the past, he was chairman of the department of molecular and human genetics of Baylor College of Medicine, senior vice president of human genetics and vaccines discovery at Merck Research Laboratories, president of the Merck Genome Research Institute, president of the American Society of Human Genetics, and president of the Human Genome Organization. Caskey holds a medical degree from the Duke University School of Medicine and a degree from the Universityof South Carolina.


 

Gilbert Omenn has joined the board of directors of OccuLogix, the company said on Monday. He is a professor of internal medicine, human genetics, and public health at the Universityof Michigan. He also leads the plasma proteome project of the Human Proteome Organization and is a member of its council. Earlier this year, he became president of the American Association for the Advancement of Science. Omenn holds an MD from Harvard Medical School, a PhD in genetics from the Universityof Washington, and a BA fro PrincetonUniversity.


 

Robert Tien, a director of Orchid BioSciences, will not stand for re-election at the company's next annual meeting of stockholders, Orchid said in an SEC filing earlier this month.


 

Mary Jane Cunningham and Mark Banaszak Holl have received a $75,000 award from the National Academies Keck Futures Initiative to assess the safety of dendrimers by toxicogenomics, the initative said last week. They project is one of fourteen research projects receiving a total of $1 million for interdisciplinary research on nanoscience and nanotechnology. The awards are funded by a $40 million grant from the W.M. Keck Foundation.

 

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.